Efficacy of Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) and Recombinant Human Granulocyte Macrophage Colony Stimulating Factor (rhGM-CSF) in Neutropenic Children with Malignancies.
- Author:
Gyung Hoon LEE
1
;
Kwang Hae CHOI
;
Jeong Ok HAH
Author Information
1. Department of Pediatrics, College of Medicine, Yeungnam University, Taegu, Korea.
- Publication Type:Original Article
- Keywords:
rhG-CSF;
rhGM-CSF;
Neutropenia
- MeSH:
Abdominal Pain;
Agranulocytosis;
Blood Cell Count;
Child*;
Clone Cells;
Colony-Stimulating Factors*;
Drug Therapy;
Fever;
Granulocyte-Macrophage Colony-Stimulating Factor*;
Granulocytes*;
Humans*;
Intercellular Signaling Peptides and Proteins;
Monocytes;
Myalgia;
Neutropenia;
Neutrophils
- From:Korean Journal of Pediatric Hematology-Oncology
1999;6(1):20-30
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Current intensive anticancer therapy may cause myelosuppression with an increased risk of severe infections. As a result, the administration of chemotherapy in cancer patients might be delayed often. Hemopoietic growth factors, which are responsible for the differentiation and functional regulation of granulocytes and monocytes, have been cloned and are available as rhG-CSF and rhGM-CSF. The aim of this study was to compare the efficacy and side effects of rhG-CSF and rhGM-CSF in children with cancer who received chemotherapy. METHODS: The study included 55 children ranging in age from 2 to 18 years who received chemotherapy for cancer and had absolute neutrophil count (ANC) under 500/muL. The growth-factors were administered subcutaneously starting in doses of 5~10 mug/ kg/day. The ANC was determined by complete blood counts starting on the first day of administration and every other day thereafter until the ANC rose above 1,000/muL. RESULTS: There was no significant difference in the mean days for increase of the mean ANC value >500/muL (5.0+/-2.9 vs 5.7+/-4.2 days) and >1,000/muL (5.9+/-3.2 vs 6.4+/-4.8 days) after rhG-CSF and rhGM-CSF respectively. Side effects of rhG-CSF and rhGM-CSF were fever, myalgia, bone pain, elevation of ALT and rGT and abdominal pain in order and there was no difference between two growth factors. Also the numbers of transfusion of packed RBCs (0.7+/-0.8 vs 0.7+/-0.8) and platelets (0.8+/-1.0 vs 0.6+/-0.9) were not different after the two growth factors. CONCLUSION: It seems to be that rhG-CSF and rhGM-CSF are comparable in clinical effects and side effects when used for granulocytopenia in children with cancer.
